Health Care [ 4/12 ] | Biotechnology [ 14/75 ]
NASDAQ | Common Stock
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL).
In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 26 | -0.17 Increased by +39.29% | -0.23 Increased by +24.61% |
| Nov 6, 25 | -0.19 Increased by +40.63% | -0.22 Increased by +13.64% |
| Aug 13, 25 | -0.23 Increased by +34.29% | -0.27 Increased by +14.81% |
| May 12, 25 | -0.28 Increased by +26.32% | -0.41 Increased by +31.71% |
| Mar 12, 25 | -0.28 Increased by +34.88% | -0.32 Increased by +13.42% |
| Nov 7, 24 | -0.32 Increased by +13.51% | -0.33 Increased by +3.03% |
| Aug 7, 24 | -0.35 Increased by +33.96% | -0.35 |
| May 13, 24 | -0.38 Increased by +44.12% | -0.41 Increased by +7.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Increased by +100.00% | -38.81 M Increased by +35.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -41.40 M Increased by +37.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -50.94 M Increased by +23.23% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -59.73 M Increased by +8.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -22.00 K Increased by +50.00% | -59.94 M Increased by +32.85% | Increased by +272.45 K% Increased by +34.31% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -66.29 M Decreased by -6.43% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -66.36 M Increased by +16.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 22.00 K Decreased by -26.67% | -65.00 M Increased by +34.98% | Decreased by -295.45 K% Increased by +11.34% |